Cevipabulin
CAS No. 849550-05-6
Cevipabulin( —— )
Catalog No. M32838 CAS No. 849550-05-6
Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 61 | In Stock |
|
| 5MG | 51 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCevipabulin
-
NoteResearch use only, not for human use.
-
Brief DescriptionCevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).
-
DescriptionCevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line.
-
In VitroCevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC50 values) on cell lines from ovarian, breast, prostate, and cervical tumors.Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block.Cell Cytotoxicity Assay Cell Line:Human cancer cell lines (SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP, and Hela cells).Concentration:0-50 nM Incubation Time:72 hours Result:The IC50 values are 24±8 nM, 21±4 nM, 18±6 nM, 22±7 nM and 40 nM in SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP and Hela cells.
-
In VivoCevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.Animal Model:Athymic nu/nu female mice implanted s.c. in the flank with 1×107 LoVo human colon adenocarcinoma cells Dosage:5, 10, 15, and 20 mg/kg Administration:I.V. injection every 4 days for 4 cycles.Result:The compound showed dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.Animal Model:Athymic nu/nu female mice implanted s.c. in the flank with 1×106 U87-MG human glioblastoma cells.Dosage:25 mg/kg Administration:P.O. or I.V.Result:The compound was active by p.o. or i.v. administration against human tumor xenografts.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMicrotubule Associated
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number849550-05-6
-
Formula Weight464.82
-
Molecular FormulaC18H18ClF5N6O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 16.67 mg/mL (35.86 mM; Ultrasonic )
-
SMILES[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300.?
molnova catalog
related products
-
DS-1040
DS-1040 (DS1040)?is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa.
-
Fucoidan
Fucoidan is found in various species of brown seaweed and algaewith anticancer antiviral neuroprotective immune-modulating.
-
PLH1215
PLH1215 is an effective AHR inhibitor that can be used to modulate, limit, or suppress the expression of AVIL (advillin). PLH1215 can be employed for the prevention and treatment of cancer.
Cart
sales@molnova.com